Drug Profile

ES 028

Alternative Names: ES-028

Latest Information Update: 29 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Solid tumours

29 Dec 2021 Elpiscience Biopharmaceuticals plans global clinical trials in Solid tumours (for Monotherapy and Combination therapy) (Elpiscience Biopharmaceuticals pipeline, December 2021)
30 Jul 2021 ESC 028 is available for licensing as of 30 Jul 2021. (Elpiscience Biopharmaceuticals, July 2021)
30 Jul 2021 Preclinical trials in Solid tumours in China (unspecified route) (Elpiscience Biopharmaceuticals July 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com